In this P01 resubmission proposal entitled "Pathobiology of Neurodegeneration in C9ORF72 Repeat Expansion," we seek to evaluate the mechanisms of C9ORF72 expanded repeats, the most common cause of amyotrophic lateral sclerosis (ALS) and front temporal dementia (FTD), to improve the diagnosis of and prognosis for patients suffering from c9FTD/ALS. We have assembled a world-class team combining expertise in neurology, genetics, neuropathology, and cell biology that has worked closely together and has all resources in place. Our significant progress to elucidate how expanded repeat RNA transcripts and epigenetic changes may respectively drive toxicity and haploinsufficiency in c9FTD/ALS has led to the discovery that repeat expansion size does affect disease severity, and the identification of a potential biomarker detectable in blood of c9FTD/ALS patients. We now present evidence that aberrant methylation of histone 3 at lysine 9 is detectable in brain tissue, fibroblasts and blood of C9ORF72 mutation carriers. We also identified TMEM106B as the first genetic modifier of disease phenotype in C9FTD/ALS. In drawing upon the strengths of the Mayo Clinic Neurology Department, we have begun longitudinal studies of 44 C9ALS pedigrees to determine whether expansion size, tri-methylation of histone lysine residues, mRNA expression levels and TMEM106B genotypes, correlate with phenotypic variability in c9FTD/ALS. In addition, we have since produced and characterized antibodies critical for detecting each of the five repeat-associated non-ATG (RAN) translation peptides [poly(GP), poly(GA), poly(GR), poly(PA) and poly(PR)] in cell and animal models as well as human tissue. We also provide evidence that ubiquilin-2, tau and p62/sequestosome are present in neuronal inclusions in various brain regions and spinal cord, indicating that these proteins, in addition to TDP-43, may play a role in pathogenesis of front temporal lobar degeneration with TDP-43 pathology (FTLD-TDP). We provide preliminary data that TDP-43-negative/C9RANT-positive neuronal inclusions can also be detected with antibodies to dimethylarginine, suggesting a new disease mechanism involving non-histone protein methylation. Simply put, our multi-disciplinary studies will improve understanding of C9ORF72-related neurodegeneration, identify potential biomarkers and therapeutic targets, and develop a compelling brain, biofluid and biopsy resource to aid future drug discovery.

Public Health Relevance

Amyotrophic lateral sclerosis (ALS) is an incurable disease of nerve cells that control muscles. Some patients with ALS have mental and behavioral abnormalities similar to frontotemporal dementia (FTD). Researchers in this program project aim to discover the cellular disease processes initiated by mutations in the C9ORF72 gene in order to improve the diagnosis of and prognosis for patients suffering from disorders collectively referred to as c9FTD/ALS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
1P01NS084974-01A1
Application #
8754964
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Sutherland, Margaret L
Project Start
2014-09-30
Project End
2019-06-30
Budget Start
2014-09-30
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
$1,291,133
Indirect Cost
$466,128
Name
Mayo Clinic Jacksonville
Department
Type
DUNS #
153223151
City
Jacksonville
State
FL
Country
United States
Zip Code
32224
Tian, Feng; Yang, Wenlong; Mordes, Daniel A et al. (2016) Monitoring peripheral nerve degeneration in ALS by label-free stimulated Raman scattering imaging. Nat Commun 7:13283
Vatsavayai, Sarat C; Yoon, Soo Jin; Gardner, Raquel C et al. (2016) Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139:3202-3216
Lopez-Gonzalez, Rodrigo; Lu, Yubing; Gendron, Tania F et al. (2016) Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron 92:383-391
Graff-Radford, Jonathan; Lesnick, Timothy G; Boeve, Bradley F et al. (2016) Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Mov Disord 31:989-94
Kramer, Nicholas J; Carlomagno, Yari; Zhang, Yong-Jie et al. (2016) Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science 353:708-12
Mohagheghi, Fatemeh; Prudencio, Mercedes; Stuani, Cristiana et al. (2016) TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. Hum Mol Genet 25:534-45
Esanov, Rustam; Belle, Kinsley C; van Blitterswijk, Marka et al. (2016) C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. Exp Neurol 277:171-7
Zhang, Yong-Jie; Gendron, Tania F; Grima, Jonathan C et al. (2016) C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci 19:668-77
Belzil, Veronique V; Katzman, Rebecca B; Petrucelli, Leonard (2016) ALS and FTD: an epigenetic perspective. Acta Neuropathol 132:487-502
Walton, Ronald L; Soto-Ortolaza, Alexandra I; Murray, Melissa E et al. (2016) TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurol Genet 2:e85

Showing the most recent 10 out of 22 publications